Company intelligence / Profile preview

MIRTO

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Mirto is a biotechnology company focused on developing a new class of cancer therapeutics that target the mRNA translation machinery. Founded by Dr. Davide Ruggero, a pioneer in the field of protein synthesis and cancer, the company leverages insights into how aberrant translation drives tumor growth and survival. Mirto's primary focus is on inhibiting the eIF4F initiation complex, specifically targeting eIF4E, to selectively block the production of oncogenic proteins. By modulating the "translatome," the company aims to provide more effective treatments for a wide range of aggressive and drug-resistant cancers.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MIRTO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIRTO.

Explore the full profile